Jasmine Fels (for Ellie Merle)'s questions to Altimmune Inc (ALT) leadership • Q4 2024
Question
Jasmine Fels from UBS Group AG asked for confirmation on the timeline for the new indications, specifically if the Phase II trials could produce proof-of-concept data in 2026 and whether a third indication might still be pursued.
Answer
CEO Dr. Vipin Garg clarified that the current focus is on the two cleared INDs. CMO Dr. Scott Harris confirmed both are Phase II proof-of-concept studies and that they expect data from at least one of them in 2026, with a second being a possibility.